MRNA Jul 2024 145.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

8.30

+3.28

(+65.34%)

As of 12:20PM EDT. Market open.

Loading interactive chart...

Zacks
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
Zacks
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
Investor's Business Daily
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Moderna is on the rise after the Food and Drug Administration delayed a decision on its RSV vaccine. But is MRNA stock, once again, a buy?